The Role of CTCF Binding Sites in the 3' Immunoglobulin Heavy Chain Regulatory Region
Overview
Authors
Affiliations
The immunoglobulin heavy chain locus undergoes a series of DNA rearrangements and modifications to achieve the construction and expression of individual antibody heavy chain genes in B cells. These events affect variable regions, through VDJ joining and subsequent somatic hypermutation, and constant regions through class switch recombination (CSR). Levels of IgH expression are also regulated during B cell development, resulting in high levels of secreted antibodies from fully differentiated plasma cells. Regulation of these events has been attributed primarily to two cis-elements that work from long distances on their target sequences, i.e., an ∼1 kb intronic enhancer, Eμ, located between the V region segments and the most 5' constant region gene, Cμ; and an ∼40 kb 3' regulatory region (3' RR) that is located downstream of the most 3' C(H) gene, Cα. The 3' RR is a candidate for an "end" of B cell-specific regulation of the Igh locus. The 3' RR contains several B cell-specific enhancers associated with DNase I hypersensitive sites (hs1-4), which are essential for CSR and for high levels of IgH expression in plasma cells. Downstream of this enhancer-containing region is a region of high-density CTCF binding sites, which extends through hs5, 6, and 7 and further downstream. CTCF, with its enhancer-blocking activities, has been associated with all mammalian insulators and implicated in multiple chromosomal interactions. Here we address the 3' RR CTCF-binding region as a potential insulator of the Igh locus, an independent regulatory element and a predicted modulator of the activity of 3' RR enhancers. Using chromosome conformation capture technology, chromatin immunoprecipitation, and genetic approaches, we have found that the 3' RR with its CTCF-binding region interacts with target sequences in the V(H), Eμ, and C(H) regions through DNA looping as regulated by protein binding. This region impacts on B cell-specific Igh processes at different stages of B cell development.
Liang Z, Zhao L, Ye A, Lin S, Zhang Y, Guo C Proc Natl Acad Sci U S A. 2023; 120(26):e2306564120.
PMID: 37339228 PMC: 10293834. DOI: 10.1073/pnas.2306564120.
DAddabbo P, Frezza D, Sulentic C Front Immunol. 2023; 14:996119.
PMID: 36817426 PMC: 9936319. DOI: 10.3389/fimmu.2023.996119.
Nuclear architecture and the structural basis of mitotic memory.
Soujanya M, Bihani A, Hajirnis N, Pathak R, Mishra R Chromosome Res. 2023; 31(1):8.
PMID: 36725757 DOI: 10.1007/s10577-023-09714-y.
Enhancing B-Cell Malignancies-On Repurposing Enhancer Activity towards Cancer.
Kasprzyk M, Sura W, Dzikiewicz-Krawczyk A Cancers (Basel). 2021; 13(13).
PMID: 34210001 PMC: 8269369. DOI: 10.3390/cancers13133270.
Physiological role of the 3'IgH CBEs super-anchor in antibody class switching.
Zhang X, Yoon H, Chapdelaine-Williams A, Kyritsis N, Alt F Proc Natl Acad Sci U S A. 2021; 118(3).
PMID: 33441485 PMC: 7826415. DOI: 10.1073/pnas.2024392118.